tiprankstipranks

Editas Medicine reports Q4 EPS (88c), consensus (80c)

Reports Q4 revenue $6.54M, consensus $3.26M .Cash, cash equivalents, and marketable securities as of December 31, 2022, were $437.4M, compared to $478.5M as of September 30, 2022, and $619.9M as of December 31, 2021. The company expects that its existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into 2025.

Confident Investing Starts Here:

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on EDIT:

Disclaimer & DisclosureReport an Issue